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Fibrinogen storage disease (FSD) is a rare autosomal-dominant
hereditary disorder characterized by hypoﬁbrinogenemia and
accumulation of ﬁbrinogen aggregates within the hepatocellular
endoplasmatic reticulum (ER). Some FSD patients present with
elevated amino-transferases and ﬁbrosis/cirrhosis similar to
alpha-1-antitrypsin deﬁciency (ATD), also an ER storage disease.
Pharmacological stimulation of autophagy has been shown to
mediate clearance of protein aggregates and halt progression of
liver ﬁbrosis in in vivo models of ATD. Our aim was to evaluate
the presence of autophagy and a possible response to autoph-
agy-enhancing therapy in patients with FSD.
Hepatic ﬁbrosis was assessed by transient elastography in 2
newly identiﬁed FSD families with ﬁbrinogen Aguadilla and Bre-
scia mutations, encompassing 8 affected members. Available liver
biopsies were assessed for autophagy. Two patients, who had had
elevated alanine amino-transaminase levels (2–5 above upper
limit of normal), were treated with the autophagy enhancer car-
bamazepine (CBZ).
Transient elastography did not show evidence of signiﬁcant
ﬁbrosis in any affected family members. Quantitative electron
microscopy of one patient showed a 5.15-fold increase of late
stage autophagocytic vacuoles compared to control livers. CBZ
at low anticonvulsive treatment levels led to rapid normalizationJournal of Hepatology 20
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uncleaved cytokeratin-18 fragments (M30 and M65). These
effects reversed after discontinuation of treatment.
Response to CBZ may be mediated by pharmacologically
enhanced autophagy resulting in reduction of aggregate-related
toxicity in FSD. These results suggest clinical applicability of
pharmacological stimulation of autophagy in FSD, but potentially
also in other related disorders.
 2013 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
Fibrinogen storage disease (FSD) is a rare autosomal-dominant
hereditary disorder characterized by hypoﬁbrinogenemia and
accumulation of ﬁbrinogen precursor proteins within the hepa-
tocellular endoplasmatic reticulum (ER). Four mutations within
the ﬁbrinogen gamma chain (FGC) gene that cause protein
aggregation, ER retention, and consequent hypoﬁbrinogenemia
in heterozygous individuals have been identiﬁed to date:
ﬁbrinogen Brescia (c284 Gly?Arg), ﬁbrinogen Aguadilla (c375
Arg?Trp), ﬁbrinogen AI DuPont (c314 Thr?Pro) and ﬁbrinogen
Angers (cdel346-350) [1,2]. Aggregated ﬁbrinogen is visible as
small faintly eosinophilic coarse globules on hematoxylin/eosin
(H&E) stained sections. Using transmission electron microscopy
(TEM), a diagnostic ‘‘ﬁngerprint-like’’ pattern can be seen
within the ER. To date 26 individuals have been described
(Supplementary data). Patients show variable severity in liver
disease ranging from an inert carrier state to cirrhosis (Supple-
mentary data).
Macroautophagy (referred to hereafter as autophagy) is a
highly conserved and regulated cellular clearance mechanism
[3]. Non-selective autophagy mediates metabolic adaption to dif-
ferent nutritional conditions and maintains cellular homeostasis.
Selective autophagy clears aggregated and misfolded proteins as
well as damaged organelles via cytosolic sequestration and sub-
sequent lysosomal degradation.13 vol. 59 j 626–630
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In murine models of hepatic alpha-1-antitrypsin deﬁciency
(ATD), autophagy-enhancing drugs carbamazepine (CBZ) and
rapamycin reduced the hepatocellular burden of aggregated pro-
tein as well as liver ﬁbrosis [4,5].
FSD and ATD share a similar pathogenesis: the accumulation of
aggregated misfolded proteins within the endoplasmatic reticu-
lum and development of progressive ﬁbrotic liver disease [6]. In
a yeast model of FSD, autophagy contributes to endoplasmatic
reticulumclearance of ﬁbrinogenAguadilla gamma chain [7]. Here
we characterize twonewly identiﬁed FSD families andevaluate the
effects of pharmacological stimulation of autophagy by CBZ in
affected members with elevated serum amino-transferases.Fig. 1. Histology and TEM of liver biopsies. (A) Liver biopsy of F2 III-1 showing
coarse inclusions, H&E original magniﬁcation (OM) 200; (B) apoptosis (arrow),
mitosis (arrowhead), F1 III-4, H&E OM 400; (C) necroinﬂammatory activity
(arrow), F1 III-4, H&E OM 100; (D) focal periportal ﬁbrosis, F1 III-4, Elastic Van
Gieson (EVG) OM 100; (E) aggregates show densely packed curved tubules
diagnostic of FSD (F1 III-4); (F, G) late stage autophagocytic vacuoles in FSD
containing aggregates as cargo (F2 III-1); (H) rare autophagocytic vacuole in a
control liver (control patient 1); (I) autophagocytic vacuoles in an explanted liver
of a 8-month old infant with severe neonatal ATD. Bars = 500 nm.Patients and methods
Patients
Probands of both families, a 6-year old girl and a 5-year old boy, were referred to
a tertiary institution for investigation of persistently elevated serum aminotrans-
ferases. Diagnostic liver biopsies were performed, which led to diagnoses of FSD.
Tissue for parafﬁn sections was formalin-ﬁxed, parafﬁn-processed and stained
using routine procedures and stains. For quantiﬁcation of autophagy, control liver
tissue was obtained from 3 children with normal/nearly normal diagnostic liver
biopsies and an 8-month old infant, who underwent liver transplantation for
severe ATD (Supplementary data). Tissue for TEM was ﬁxed in glutaraldehyde
(patient F2 III-1, control patients 1-3, control ATD patient) or deparafﬁnized
(patient F1 III-4) and processed using standard osmium tetroxide treatment,
epon resin embedding and uranyl acetate/lead citrate staining.
Genetic testing
Genetic testing was performed for subtyping of FSD in the probands and their fam-
ilies. Informed consent according to the German Genetic Diagnosis Act was
obtained on all members tested. Genomic DNAwas isolated from EDTA blood sam-
ples. Exons 8 and 9 of the ﬁbrinogen gamma gene were ampliﬁed and both strands
were sequenced by conventional dideoxy Sanger sequencing using a GenomeLab
GeXP capillary sequencer (Beckman Coulter, Krefeld, Germany). Oligonucleotide
primers used for ampliﬁcation and sequencing were: exon 8 forward: 50- AGGGTC
AGCATGTGATGGTT -30; and reverse: 50- TCCACTTCCAGTTTCAAAGAA -30 , and exon
9 forward: 50- ACTGGCAATGCACTTCGTAA -30; and reverse: 50- AAAAAGGAAGA
AACTTTCAGAGAA -30 .
Transient elastography
Liver stiffness was measured by transient elastography (FibroScan, Echosens,
France) using the XL probe for F1 I-2, the M probe for all other adults, and the
S probe (S2 setting) for children. Ten consecutive measurements were performed
on each patient and the median and interquartile ranges (IQR) were calculated.
Liver stiffness measurements of <6 kPa (618 years) and <7 kPa (>18 years) were
regarded as normal (Supplementary data).
Carbamazepine treatment
Initiation of CBZ treatment was approved by the institutional ethics committee of
Hannover Medical School and informed consent was obtained from parents of
treated patients. Daily doses of CBZ were increased incrementally from
2  20 mg to maintenance doses of 2  150 mg (14.2 mg kg1 d1, F2 II-1) and
2  200 mg (15.8 mg kg1 d1, F1 III-4). Duration of CBZ treatment was 219 days
for F1 III-4 and 208 days for F2 II-1.
Cytokeratin-18 detection
For quantiﬁcation of uncleaved and caspase-cleaved cytokeratin-18 within
patients’ sera, the M30 Aptosense and M65 ELISAs (Peviva, Bromma, Sweden)
were used as described [8]. Sera from 9 healthy children (5.7–8.8 years, mean
age 6.4 years) were used as control group.Journal of Hepatology 201Case report
Clinical history of probands
The proband of family 1 (F1 III-4), a 6-year old Caucasian girl, was
found to have persistently elevated serum alanine aminotransfer-
ase (ALT) levels as well as prolonged prothrombin time on routine
blood tests. Themedical historywasunremarkable. Theprobandof
family 2 (F2 III-1), a 5-year old Caucasian boy, presented with
repeated and prolonged episodes of epistaxis. Investigations for
exclusion of a coagulopathy revealed hypoﬁbrinogenemia and ele-
vated ALT levels. Serologies for autoimmune hepatitis or hepato-
trophic viruses were negative in both patients and none of them
received any medication.
Diagnostic liver biopsies
The liver biopsies of both probands showed hepatocytes with
granular cytoplasm and focal coarse irregular globules (Fig. 1A).
F1 III-4’s biopsy showed scattered apoptotic hepatocytes, mito-
ses, and necroinﬂammatory foci in low density (Fig. 1B and C).
There was mild nodular regenerative hyperplasia and minimal
collagenous expansion of portal tracts (Fig. 1D).
Transmission electron microscopy
In both patients, material examined by TEM showed aggregates
of curved tubular ‘‘ﬁngerprint-like’’ structures within the dis-
tended ER (Fig. 1E). Poor preservation of membranous structures
in the biopsy of F1 III-4 due to re-embedding of parafﬁn-pro-
cessed tissue rendered this sample unsuitable for detection of3 vol. 59 j 626–630 627
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Fig. 2. Family trees of both FSD families and parameters during CBZ treatment. (A) Family 1, ﬁbrinogen Aguadilla, affected members in 3 generations; (B) Family 2, de
novo ﬁbrinogen Brescia mutation in 2 generations, (affected heterozygous individuals are highlighted by half-ﬁlled symbols, tested individuals with wild type sequences are
highlighted by non-ﬁlled divided symbols, probands are indicated by arrows, n.t., not tested); (C) CBZ led to rapid normalization of ALT, which relapsed to pre-treatment
levels after cessation of CBZ (dotted line = upper limit of normal); (D) hypoﬁbrinogenemia did not change during CBZ treatment, x indicates ﬁbrinogen levels below the
limit of detection (<0.5 g/L). (E) Monitoring of serum CBZ levels showed levels below the therapeutic window recommended for anticonvulsant therapy. (F) Decline of M65
and (G) M30 during CBZ treatment. d0 = start of CBZ; light blue box, duration of CBZ treatment.
Case Reportautophagocytic vacuoles. Material of F2 III-1 showed late stage
autophagocytic vacuoles with aggregates as cargo and electron
dense multilamellar structures indicative of previous lysosomal
fusion (degradative autolysosomes) (Fig. 1F and G). Quantitative
morphometry showed a 5.15 increase in density of autophagocy-
tic vacuoles in FSD (F2 III-4) and 2.81 increase in one ATD patient
compared to normal/near normal pediatric liver biopsies (Supple-
mentary data).
Fibrinogen gamma mutations of probands and relatives
Family 1: Sequencing detected a heterozygous CGG? TGG tran-
sition at codon 375 in exon 9 of the FGC gene (ﬁbrinogen Aguadil-
la) in the proband and in ﬁve additional family members in three
generations (Fig. 2A, Supplementary data).
Family 2: Sequencing detected a heterozygous GGG? AGG tran-
sition in exon 8 in the proband (F2 III-1) and his father (F2 II-2).
This transition causes a Gly? Arg substitution at codon 284628 Journal of Hepatology 201(ﬁbrinogen Brescia). This mutation differs from the GGG? CGG
transversion that was found in the only other ﬁbrinogen Brescia
family described so far [9]. Mutations were not detected in the
grand-parents (F2 I-1 and F2 I-2) of the proband, indicative of a
de novomutation appearing in the father (Fig. 2B, Supplementary
data).
Clinical assessment of affected family members
Liver disease had not been suspected in any family member
except the probands prior to this investigation. All affected family
members showed hypoﬁbrinogenemia (Supplementary data).
Transient elastography
None of the patients exceeded normal range cut-off values, there-
fore providing no evidence of signiﬁcant liver ﬁbrosis (Supple-
mentary data).3 vol. 59 j 626–630
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CBZ treatment
Oral CBZ treatment led to rapid normalization of ALT levels
(Fig. 2C) and aspartate aminotransferase (AST) levels (Supple-
mentary data) in F1 III-4 and F2 III-1. Time to normalization
was 35 and 26 days for F1 III-4 and F2 III-1, respectively. No sig-
niﬁcant change in ﬁbrinogen levels and international normalized
ratio (INR) levels were observed during CBZ treatment (Fig. 2D,
Supplementary data). Levels of serum albumin, bilirubin, c-glut-
amyltransferase, and alkaline phosphatase remained unchanged
(not shown). The levels of surrogate markers for apoptosis and
necrosis, M30 and M65 steadily decreased during treatment
(Fig. 2G and F). M30 and M65 levels did not differ signiﬁcantly
from healthy controls (M30: 141 ± 33; M65 359 ± 63,
mean ± standard error of the mean). After discontinuation of
CBZ treatment, the effects on ALT, M30, and M65 reversed
(Fig. 2C, G and F). Serum CBZ concentrations when receiving
maintenance doses were 1.5–4.5 lg ml1 (median 3.35) for F1
III-4 (the level of 1.5 lg ml1 leading to dose adjustment from
2  140 mg d1 to 2  200 mg d1). CBZ levels for F2 III-1 were
3.2–7.0 lg ml1 (median 4.45 lg ml1) (Fig. 2E). Liver stiffness
measurements performed on F1 III-4 and F2 III-1 during treat-
ment (days 104 and 219 in F1 III-4 and days 111 and 208 in F2
III-1) showed unchanged non-pathological results (4.95 kPa and
4.7 kPa in F1 III-4; 4.5 kPa and 5.5 kPa in F2 III-1).Discussion
With only 26 affected individuals reported in the English litera-
ture, FSD qualiﬁes as an orphan disease rendering controlled ran-
domized trials unfeasible. The rationales justifying tentative
uncontrolled and non-blinded initiation of CBZ treatment were:
(i) the salient analogies with ATD, in particular increase in autoph-
agy, (ii) evidence of persistent hepatocellular damage documented
by liver biopsy and elevated serum amino-transferase in 2 out of 8
newly described patients, (iii) availability of a drugwith a low-risk
proﬁle, whose effect on autophagy is well characterized in in vitro
and in vivo studies, (iv) absence of causative treatment for liver dis-
ease in FSD. We considered the risk of CBZ-related toxicity to be
low and outweighed by the advantages of a possible new treat-
ment option for liver disease in FSD. In direct comparisonwith rap-
amycin, CBZ showed a better clearance of insoluble aggregates [4].
Both patients treated with CBZ showed rapid normalization of
serum amino-transferase levels in combination with declining
levels of M30 and M65 (exceeding M30 decline). This suggests
reduction of apoptotic as well as necrotic hepatocellular death,
both of which were observed in the diagnostic pretreatment liver
biopsy of F1 III-4 (Fig. 1B and C) [8]. M30 and M65 levels before
treatment were not signiﬁcantly different from healthy individu-
als, which is in keeping with the subtle histological changes and
absence of signiﬁcant ﬁbrosis in the biopsies.
Normalization of liver function has been reported in FSD and
ATD following treatment with ursodeoxycholic acid (FSD) or a-
tocopherol and ursodeoxycholic acid (ATD) [10,11]. In these
studies, ALT and other parameters returned to normal levels over
a period of two years. In contrast, in our study ALT normalization
occurred within 4 and 5 weeks of treatment and vice versa,
suggesting a speciﬁc and direct mode of action. These may be
mediated by selective autophagocytic clearance of ER aggregates
and subsequent reduction of aggregate mediated toxicity analo-Journal of Hepatology 201gous to in vitro and in vivo models [4,5,12]. In addition, upregula-
tion of non-selective autophagy has been demonstrated to exalt
resistance against pro-apoptotic insults via enhanced clearance
of mitochondria and subsequent reduction of cytosolic cyto-
chrome c release [13]. This leads to reduction of downstream cas-
pase activity, which could explain reduced M30 levels during
treatment.
The stimulatory effect of CBZ on autophagy is dose dependent,
does not affect synthesis or secretion of mutant protein, and is
capable of further enhancing already upregulated autophagy as
seen in our patients [4]. CBZwas also shown to enhance the prote-
asomal degradation of soluble mutant protein in addition to
autophagy mediated clearance [4]. Interestingly, CBZ doses below
the therapeuticwindow recommended for anticonvulsant therapy
(6–12 lg ml1) were sufﬁcient to diminish liver damage in our
patients.
Themechanisms bywhich accumulatedmutant proteinsmedi-
ate cellular toxicity in FSD are likely to be similar to ATD [6]. In
mouse models, accumulation of polymeric mutant alpha1-anti-
trypsin Z causes ER stress, mitochondrial damage, activation of
both pro-apoptotic, as well as regenerative pathways and activa-
tion of the autophagocytic response [6,14]. Hepatocellular injury
promotes ﬁbrosis via stellate cell activation [15]. The in vivo study
in transgenic PiZmice showed reduced levels of stellate cell activa-
tion markers and markedly decreased ﬁbrosis in CBZ treated ani-
mals [4]. Therefore, decline of hepatocellular injury illustrated by
ALT, M30, andM65 levels in our FSD patients indicates attenuated
ﬁbrogenic stimuli during CBZ therapy. Most FSD patients with sig-
niﬁcant ﬁbrosis present in later life (Supplementary data). This
suggests that progression of ﬁbrosis in FSD is slow, hampering
assessment of treatment effects on progression of ﬁbrosis.
In conclusion, we provide evidence for feasibility of therapeu-
tic exploitation of pharmacological enhancement of autophagy in
FSD, which may also apply to other diseases characterized by
aggregated proteins.Conﬂict of interest
The authors who have taken part in this study declared that they
do not have anything to disclose regarding funding or conﬂict of
interest with respect to this manuscript.
Acknowledgements
The authors like to thank U. Drebber, University Hospital Cologne,
Germany for providing the liver biopsy material from F2 III-1, U.
Schmitt, Institute of Wood Technology and Wood Biology, Ham-
burg, Germany and Graham Gatward, Department of Histopa-
thology, Addenbrooke’s Hospital, Cambridge, United Kingdom
for their support in electron microscopy as well as E.-L. Eskelinen,
University of Helsinki, Finland for assessment of autophagosoms.
We are indebted to J. Le Quesne, University of Cambridge, United
Kingdom and H. Wedemeyer, Hannover Medical School, Germany
for their critical review of the manuscript.Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.jhep.2013.
05.018.3 vol. 59 j 626–630 629
Case Report
References
[1] de Moerloose P, Neerman-Arbez M. Congenital ﬁbrinogen disorders. Semin
Thromb Hemost 2009;35:356–366.
[2] Brennan SO, Davis RL, Conard K, Savo A, Furuya KN. Novel ﬁbrinogen
mutation gamma314Thr?Pro (ﬁbrinogen AI duPont) associated with
hepatic ﬁbrinogen storage disease and hypoﬁbrinogenaemia. Liver Int
2010;30:1541–1547.
[3] Ravikumar B, Sarkar S, Davies JE, Futter M, Garcia-Arencibia M, Green-
Thompson ZW, et al. Regulation of mammalian autophagy in physiology and
pathophysiology. Physiol Rev 2010;90:1383–1435.
[4] Hidvegi T, Ewing M, Hale P, Dippold C, Beckett C, Kemp C, et al. An
autophagy-enhancing drug promotes degradation of mutant alpha1-anti-
trypsin Z and reduces hepatic ﬁbrosis. Science 2010;329:229–232.
[5] Kaushal S, Annamali M, Blomenkamp K, Rudnick D, Halloran D, Brunt EM,
et al. Rapamycin reduces intrahepatic alpha-1-antitrypsin mutant Z protein
polymers and liver injury in a mouse model. Exp Biol Med (Maywood)
2010;235:700–709.
[6] Perlmutter DH. Alpha-1-antitrypsin deﬁciency: importance of proteasomal
and autophagic degradative pathways in disposal of liver disease-associated
protein aggregates. Annu Rev Med 2011;62:333–345.
[7] Kruse KB, Dear A, Kaltenbrun ER, Crum BE, George PM, Brennan SO, et al.
Mutant ﬁbrinogen cleared from the endoplasmic reticulum via endoplasmic
reticulum-associated protein degradation and autophagy: an explanation for
liver disease. Am J Pathol 2006;168:1299–1308.630 Journal of Hepatology 201[8] Joka D, Wahl K, Moeller S, Schlue J, Vaske B, Bahr MJ, et al. Prospective
biopsy-controlled evaluation of cell death biomarkers for prediction of liver
ﬁbrosis and nonalcoholic steatohepatitis. Hepatology 2012;55:455–464.
[9] Brennan SO, Wyatt J, Medicina D, Callea F, George PM. Fibrinogen brescia:
hepatic endoplasmic reticulum storage and hypoﬁbrinogenemia because of a
gamma284 Gly?Arg mutation. Am J Pathol 2000;157:189–196.
[10] Lykavieris P, Ducot B, Lachaux A, Dabadie A, Broue P, Sarles J, et al. Liver
disease associated with ZZ alpha1-antitrypsin deﬁciency and ursodeoxy-
cholic acid therapy in children. J Pediatr Gastroenterol Nutr 2008;47:
623–629.
[11] Maggiore G, Nastasio S, Sciveres M. Long term outcome of liver disease-
related ﬁbrinogen Aguadilla storage disease in a child. J Pediatr Gastroen-
terol Nutr 2011;55:699.
[12] Ravikumar B, Duden R, Rubinsztein DC. Aggregate-prone proteins with
polyglutamine and polyalanine expansions are degraded by autophagy.
Hum Mol Genet 2002;11:1107–1117.
[13] Ravikumar B, Berger Z, Vacher C, O’Kane CJ, Rubinsztein DC. Rapamycin pre-
treatment protects against apoptosis. Hum Mol Genet 2006;15:1209–1216.
[14] Hidvegi T, Mirnics K, Hale P, Ewing M, Beckett C, Perlmutter DH. Regulator of
G signaling 16 Is a marker for the distinct endoplasmic reticulum stress state
associated with aggregated mutant a1-antitrypsin Z in the classical form of
a1-antitrypsin deﬁciency. J Biol Chem 2007;282:27769–27780.
[15] Friedman SL. Mechanisms of hepatic ﬁbrogenesis. Gastroenterology 2008;
134:1655–1669.3 vol. 59 j 626–630
